L. Lin

Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa‐2a combination therapy for chronic hepatitis B

M. Buti, P. Marcellin, R. Idilman, 2016, Alimentary pharmacology & therapeutics.

Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double‐blind multicentre randomized controlled trial

B. Zhao, F. Zeng, F. Hao, 2006, The British journal of dermatology.

Atopic dermatitis (eczema) in US female nurses: lifestyle risk factors and atopic comorbidities

A. Qureshi, C. Camargo, A. Drucker, 2016, The British journal of dermatology.

Significant histopathology in Chinese chronic hepatitis B patients with persistently high–normal alanine aminotransferase

Y. Yang, Q. Xie, W. Cai, 2010, Journal of viral hepatitis.

Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B

M. Buti, W. Seto, H. Janssen, 2017 .

Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B

M. Buti, A. Gaggar, K. Agarwal, 2018 .